1. The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors.
- Author
-
Miao, Shucheng, Rodriguez, Bertha Leticia, and Gibbons, Don L.
- Subjects
NEUTROPHIL lymphocyte ratio ,CELL physiology ,NEUTROPHILS ,IMMUNOTHERAPY ,CELL proliferation ,CELLULAR signal transduction ,TUMOR markers ,IMMUNE checkpoint inhibitors ,CELL lines ,GENE expression ,METABOLITES ,LUNG cancer ,CHEMOKINE receptors ,IMMUNOSUPPRESSION ,PHENOTYPES - Abstract
Simple Summary: Lung cancer is the leading cause of cancer-related death in the U.S. and the majority of these cases are non-small-cell lung cancer (NSCLC). While immune checkpoint inhibitors (ICIs) are initially effective, patients often develop resistance to the treatment. Tumor-associated neutrophils (TANs) play a key role in the tumor environment and immune response. The main challenge is to understand how TANs influence the effectiveness of ICI treatment. This review discusses current research on how neutrophils interact with cancer cells and other components in the tumor environment. Ongoing clinical trials are exploring treatments that target these neutrophils to improve ICI therapy in NSCLC. Lung cancer is the most common cause of cancer-related death in both males and females in the U.S. and non-small-cell lung cancer (NSCLC) accounts for 85%. Although the use of first- or second-line immune checkpoint inhibitors (ICIs) exhibits remarkable clinical benefits, resistance to ICIs develops over time and dampens the efficacy of ICIs in patients. Tumor-associated neutrophils (TANs) have an important role in modulating the tumor microenvironment (TME) and tumor immune response. The major challenge in the field is to characterize the TANs in NSCLC TME and understand the link between TAN-related immunosuppression with ICI treatment response. In this review, we summarize the current studies of neutrophil interaction with malignant cells, T-cells, and other components in the TME. Ongoing clinical trials are aimed at utilizing reagents that have putative effects on tumor-associated neutrophils, in combination with ICI. Elevated neutrophil populations and neutrophil-associated factors could be potential therapeutic targets to enhance anti-PD1 treatment in NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF